Short report: Surveillance for adverse drug reactions to combination antimalarial therapy with sulfadoxine-pyrimethamine plus artesunate in Peru

Javier Cairo, Salomón Durand, Wilmer Marquiño, César Cabezas, Arnaldo Lachira, Fernando Quintana, Walter Vegas, Trenton K. Ruebush, Gregory Utz, David J. Bacon

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

4 Citas (Scopus)

Resumen

In 2001, Peru changed its treatment policy for uncomplicated Plasmodium falciparum malaria on the northern Pacific Coast to sulfadoxine-pyrimethamine with atresunate (SP-AS). Because Peru was the first country in the Americas to adopt this combination therapy, we established a surveillance system in the region to assess the frequency of new or worsening symptoms after starting therapy. Over a period of two years, 1,552, or approximately two-thirds of all patients with uncomplicated P. falciparum malaria who had received SP-AS on the northern coast were followed up. Of these, 8.8% reported at least one adverse effect, with the most common being vomiting, nausea, headache, abdominal pain, dizziness, and fever; no severe adverse effects related to SP-AS therapy were identified. Treatment of uncomplicated malaria with SP-AS was associated with a low frequency of mild adverse effects in Peru, and therefore should be considered as a first-line therapy in areas of the Americas where SP efficacy is still high.

Idioma originalInglés
Páginas (desde-hasta)42-44
Número de páginas3
PublicaciónAmerican Journal of Tropical Medicine and Hygiene
Volumen79
N.º1
DOI
EstadoPublicada - jul. 2008

Huella

Profundice en los temas de investigación de 'Short report: Surveillance for adverse drug reactions to combination antimalarial therapy with sulfadoxine-pyrimethamine plus artesunate in Peru'. En conjunto forman una huella única.

Citar esto